Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02226783 · ClinicalTrials.gov registry record · Phase 1
D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects
A Phase 1 study, sponsored by Ardelyx.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT02226783: Completed Phase 1 study, sponsored by Ardelyx.
NCT02226783 is a Phase 1 study that has completed, run by Ardelyx. The registered enrollment target is 37 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (38% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02226783, a Phase 1 study, has completed, sponsored by Ardelyx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
Study to evaluate the effect of intake of food in comparison to fasting condition on pharmacodynamics of AZD1722 following a twice-daily administration of AZD1722 tablet formulation
Primary Outcome
Sodium and phosphorus content in stool collected over 24-hour intervals
Interventions
- DRUG AZD1722 salt tablet
- DRUG AZD1722 free base tablet
- DRUG AZD1722 free base tablet + Omeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
What the finished NCT02226783 record still lists
NCT02226783 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (38% lower).
The record links to 0 conditions, and to 3 interventions - of which AZD1722 salt tablet is the first listed.
NCT02226783 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02226783 about?
NCT02226783 is a clinical study titled "D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects". Study to evaluate the effect of intake of food in comparison to fasting condition on pharmacodynamics of AZD1722 following a twice-daily administration of AZD1722 tablet formulation
What is the current status of trial NCT02226783?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2013-03. Estimated completion is 2013-10.
What interventions are being tested in trial NCT02226783?
The interventions under investigation include: AZD1722 salt tablet (DRUG), AZD1722 free base tablet (DRUG), AZD1722 free base tablet + Omeprazole (DRUG).
Who is sponsoring clinical trial NCT02226783?
This trial is sponsored by Ardelyx, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02226783's enrollment target sits among peer trials
37 1204th of 2000 higher than 791 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia